Clinical trial
Ig NextGen 10% in Idiopathic Thrombocytopenic Purpura (ITP) Patients
NCT00362349 · CSL Limited, Industry · Completed
Key facts
| NCT number | NCT00362349 |
|---|---|
| Title | Ig NextGen 10% in Idiopathic Thrombocytopenic Purpura (ITP) Patients |
| Official title | A Single-arm, Open Label, Multi-centre Study Evaluating the Efficacy and Safety of Ig NexGen 10% in Patients With Idiopathic Thrombocytopenic Purpura (ITP) |
| Lead sponsor | CSL Limited, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Idiopathic Thrombocytopenic Purpura (ITP) |
| Intervention type | Drug |
| Interventions | IgNextGen 10% |
| Enrollment | 19 |
| Start date | Jun 1, 2007 |
| Primary completion | Oct 1, 2008 |
| Completion | Oct 1, 2008 |
| First posted | Aug 10, 2006 |
| Last update posted | Jul 18, 2016 |
| Countries | Australia |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: